Phio Pharmaceuticals Corp.PHIO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · phiopharma.com
Phio Pharmaceuticals Corp. is a King of Prussia, Pennsylvania clinical-stage biopharmaceutical company developing siRNA cancer therapeutics with its proprietary INTASYL gene-silencing technology. Its lead candidate, PH-762, silences the PD-1 gene and has been evaluated in a Phase 1b trial as a non-surgical treatment for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Key ratios
ROA
-65.8%TTM
2025
-42.3%2024
-61.1%2023
-60.3%
ROE
-113.7%TTM
2025
-70.0%2024
-114.8%2023
-116.6%
Recent news
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Targeting BRD4 (PH-894)
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Track PHIO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer